|
- DLBCL high grade B cell lymphoma with MYC and BCL2 rearrangements
Lymphoma and plasma cell neoplasms - DLBCL high grade B cell lymphoma with MYC and BCL2 rearrangements
- Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of . . .
Major changes have been made in the diffuse large B-cell lymphomas (DLBCL) high-grade B-cell lymphomas (HGBL) associated with MYC and BCL2 and or BCL6 rearrangements
- Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
We performed a single-center, phase 1b–2 study of a regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed or refractory DLBCL
- MYCおよびBCL2再構成を伴う高悪性度B細胞リンパ腫 | MyPathologyReport
この記事は、MYC および BCL2 再構成を伴う高悪性度 B 細胞リンパ腫の病理レポートを読んで理解するのに役立ちます。
- MYC及BCL-2蛋白双表达对弥漫大B细胞淋巴瘤患者预后影响:倾向性评分匹配分析 - PMC
基于MYC蛋白与BCL-2蛋白在DLBCL发生发展中的重要作用,R-CHOP方案治疗下MYC与BCL-2蛋白高表达的预后不良问题已得到广泛重视。
- Double-Expressor Phenotype (BCL-2 c-MYC Co-expression) of Diffuse Large . . .
In this study, we found that a significant proportion of DLBCL had co-expression of BCL-2 and c-MYC conferring a double-expressor phenotype according to the WHO classification
- Diffuse Large B Cell Lymphoma: Role Of MYC, BCL2, BCL6 Protein . . .
The current study aims to identify patients with DLBCL for the presence of co-expression of proteins involving MYC with BCL2 and or BCL6, corresponding translocations and their prognostic impact on response to therapy and overall survival
- The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma
Both double-expressor DLBCL (DE-DLBCL), defined as overexpression of MYC and BCL2 proteins, and double-hit lymphoma (DHL), defined as a dual translocation of MYC together with BCL2 or BCL6, represent the distinct subgroups of DLBCL with inferior clinical outcomes
|
|
|